Nautilus Biotechnology Inc Market Cap ($231.60 Million)
Market Cap & Net Worth: Nautilus Biotechnology Inc (NAUT)
Nautilus Biotechnology Inc market cap. Nautilus Biotechnology Inc (NASDAQ:NAUT) has a market capitalization of $231.60 Million ($231.60 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15797 globally and #3772 in its home market, demonstrating a -27.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nautilus Biotechnology Inc's stock price $2.34 by its total outstanding shares 127255223 (127.26 Million). Also see NAUT cash flow conversion for how efficiently the company converts equity into cash flow.
Nautilus Biotechnology Inc Market Cap History (2020–2026)
Nautilus Biotechnology Inc market cap history from 2020 to 2026. Data shows change from $1.38 Billion to $297.14 Million (-21.33% CAGR). Check current stock price of Nautilus Biotechnology Inc for real-time trading data and today's change.
Index Memberships
Nautilus Biotechnology Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.01% | #424 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1547 of 3165 |
Weight: Nautilus Biotechnology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nautilus Biotechnology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nautilus Biotechnology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Nautilus Biotechnology Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NAUT by Market Capitalization
Companies near Nautilus Biotechnology Inc in the global market cap rankings as of November 4, 2026. Also see Nautilus Biotechnology Inc total assets for a full breakdown of the balance sheet.
Key companies related to Nautilus Biotechnology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Nautilus Biotechnology Inc (2020–2026)
Market capitalization of Nautilus Biotechnology Inc from 2020 to today. Between 2020 and today, Nautilus Biotechnology Inc's market cap moved from $1.38 Billion to $ 297.14 Million, with a yearly change of -21.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $297.14 Million | +19.74% |
| 2025 | $248.15 Million | +16.07% |
| 2024 | $213.79 Million | -43.81% |
| 2023 | $380.49 Million | +66.11% |
| 2022 | $229.06 Million | -65.25% |
| 2021 | $659.18 Million | -52.26% |
| 2020 | $1.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Nautilus Biotechnology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $231.60 Million USD |
| MoneyControl | $231.60 Million USD |
| MarketWatch | $231.60 Million USD |
| marketcap.company | $231.60 Million USD |
| Reuters | $231.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument,… Read more